Dr Marian Schini
MD, PhD, FHEA
Clinical Medicine, School of Medicine and Population Health
Senior Clinical Research Fellow in Bone Metabolism
+44 114 215 9698
Full contact details
Clinical Medicine, School of Medicine and Population Health
Metabolic Bone Centre Sorby Wing
Northern General Hospital
Herries Road
91直播
S5 7AU
- Profile
-
For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk
I graduated from the Medical school of the University of Patras in Greece in 2005. After 4 years of training in Internal Medicine and 4 years in Endocrinology and Diabetes, I successfully obtained my CCT in Endocrinology and Diabetes in 2014. I have been working as a clinical research fellow for the University of 91直播 since 2015, with an interest in osteoporosis and calcium metabolism disorders. During this time, I undertook a PhD focusing on the prevalence and natural history of normocalcaemic hyperparathyroidism and hypoparathyroidism, two disorders of calcium metabolism. This project was funded by The Medical Research Council Versus Arthritis Centre for Integrated Research into Musculoskeletal Ageing and the Osteoporosis 2000 Support Group.
After completing my PhD in 2020, I was appointed as an NHS consultant at the Metabolic Bone Centre at 91直播 Teaching Hospitals, but maintained my role as a fellow with the University of 91直播, to pursue my research interest in bone metabolism further.
I have been involved in several research projects in collaboration with researchers from the University of 91直播, national but also international higher institutions. These projects have led to a number of publications and awards. I am the primary investigator for the POSE study (PINP and Osteoporosis in 91直播 Evaluation), a project aiming to investigate the use of PINP to monitor osteoporosis treatment in clinical practice by non-specialist practitioners. I am also the lead investigator in studies evaluating current osteoporosis treatments further, like denosumab and zoledronic acid. I have supported and continue to support a number of clinical trials as both a primary and sub-investigator. Some of these studies are on rare disorders of bone metabolism like X-linked hypophosphataemia and osteogenesis imperfecta, for which I have developed a special interest.
- Research interests
-
My research interests are osteoporosis, calcium metabolism disorders and rare bone metabolism disorders like X-linked hypophosphataemia and hypophosphatasia.
My PhD work was around the prevalence and natural history of normocalcaemic hyperparathyroidism and hypoparathyroidism. This project provided some further understanding of these two newly described conditions which can help in their monitoring and treatment. Due to my interest and growing experience in these disorders, I was asked to assist in preparing the next international guidelines on normocalcaemic hyperparathyroidism
I was also involved in a number of systematic reviews and meta-analyses to evaluate the risk of fractures in patients with different chronic conditions like Parkinson鈥檚 disease and diabetes mellitus. These studies were performed in collaboration with ScHARR and the team of Dr Steve Cummings in the University of California.
Throughout the years, I provided support and continue to support various clinical trials around bone metabolism like:
- Primary investigator in the clinical trial: 鈥楾he BUR02 study: A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH)
- Sub-investigator in the clinical trial 鈥淭OPaZ: Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid鈥
- Sub-investigator in the clinical trial 鈥淭he STAG Study: Phase II Study of the Impact of AZD4017, A Selective 11尾-HSD1 Inhibitor, on Biochemical Markers of Bone Turnover in Post-Menopausal Osteopenia鈥
- Sub-investigator in the clinical trial 鈥淎XLES: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and safety of KRN23 in Adults with X-linked Hypophosphatemia (XLH)鈥
- Sub-investigator in the 鈥淪eMS study: Double-blind, randomised, placebo-controlled trial on the effect of selenium supplementation on musculoskeletal health in older women鈥
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
All publications
Journal articles
- . Gaceta M茅dica de M茅xico, 160(4).
- . Journal of the Endocrine Society, 8(Supplement_1).
- . Archives of Osteoporosis, 18(1), 144.
- . Bone, 168, 116651-116651.
- . Lancet Diabetes and Endocrinology.
- . Bone, 116347-116347.
- . Osteoporos Int.
- . Bone Reports, 14, 101002.
- . Nutrients, 13(2).
- . European Journal of Endocrinology, 184(1), K7-K10.
- . Bone, 141.
- . Bone Reports, 13, 100347-100347.
- . Bone Reports, 13, 100457-100457.
- . American Journal of Kidney Diseases, 76(4), 521-532.
- . Clinical Endocrinology.
- . Bone, 137.
- . The Journal of Clinical Endocrinology & Metabolism, 105(7).
- . Clinical Endocrinology.
- . The Journal of Clinical Endocrinology & Metabolism, 105(4).
- . Bone, 132.
- . The Journal of Clinical Endocrinology & Metabolism, 100(2), E282-E286.
- . Journal of Viral Hepatitis, 21(9), 624-632.
- . Leukemia & Lymphoma, 54(7), 1541-1543.
- . Arthritis & Rheumatism, 64(12), 4066-4071.
- . The Journal of Clinical Endocrinology & Metabolism, 97(4), E618-E621.
- . Journal of Bone and Mineral Research.
- . Journal of Bone and Mineral Research.
- . Journal of Bone and Mineral Research.
- . Osteoporosis International.
- . Current Opinion in Endocrinology, Diabetes & Obesity.
- . Journal of Bone and Mineral Research.
- . Journal of Bone and Mineral Research.
- . Osteoporosis International.
- . Endocrine Abstracts.
- . Journal of Endocrinological Investigation.
- . Endocrine Reviews.
- . Endocrine Abstracts.
- . Endocrine Abstracts.
- . Journal of Bone and Mineral Research.
- . The Journal of Clinical Endocrinology & Metabolism.
- . Osteoporosis International.
Conference proceedings papers
- The association between treatment-related differences in total hip bone mineral density change and fracture risk reduction for BMD measurement intervals of 12, 18 and 24 months: the FINH-ASBMR SABRE Project. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 240-240)
- Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: Results from the FNIH-ASBMR SABRE Project. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 66-66)
- Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: Results from the FNIH-ASBMR SABRE Project. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 10-11)
- Renal Safety Of Zoledronic Acid In Patients With Borderline Kidney Function At A Metabolic Bone Centre In The United Kingdom. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 271-271)
- Monitoring Bisphosphonate Treatment In Primary Care: PINP And Osteoporosis In 91直播 Evaluation (POSE Study). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 64-65)
- RENAL SAFETY OF ZOLEDRONIC ACID IN PATIENTS WITH BORDERLINE KIDNEY FUNCTION AT A METABOLIC BONE CENTRE IN THE UK. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S194-S195)
- MONITORING BISPHOSPHONATE TREATMENT IN PRIMARY CARE: PINP AND OSTEOPOROSIS IN SHEFFIELD EVALUATION (POSE STUDY). OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S288-S288)
- . Medicine
- . Journal of the Endocrine Society, Vol. 4(Supplement_1). San Francisco, CA, USA, 28 March 2020 - 31 March 2020.
- THE RISK OF HIP AND NON-VERTEBRAL FRACTURES IN PARKINSON'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 31(SUPPL 1) (pp S55-S55)
- NORMOCALCEMIC HYPERPARATHYROIDISM: STUDY OF THE PREVALENCE AND NATURAL HISTORY. OSTEOPOROSIS INTERNATIONAL, Vol. 31(SUPPL 1) (pp S192-S192)
- Normocalcaemic hyperparathyroidism (NPHPT) and primary hyperparathyroidism (PHPT): Least significant change (LSC) for adjusted serum calcium. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 35 (pp 55-55)
- The Risk of Hip and Non-Vertebral Fractures in Parkinson's Disease: A Systematic Review and Meta-Analysis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 103-103)
- The Risk of Hip and Non-Vertebral Fractures in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 25-25)
- NORMOCALCAEMIC HYPERPARATHYROIDISM: STUDY OF THE PREVALENCE AND NATURAL HISTORY IN A UNITED KINGDOM REFERRAL POPULATION. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp 627-627)
- ADULT HYPOPHOSPHATASIA: A DISEASE WHERE THE CLINICAL COMPLICATIONS COULD BE AVOIDED BY CAREFUL EVALUATION OF PATIENTS. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp 632-633)
- Normocalcaemic Hyperparathyroidism: Study Of The Prevalence And Natural History In A United Kingdom Referral Population. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 129-129)
- NORMOCALCAEMIC HYPERPARATHYROIDISM: PREVALENCE IN A UNITED KINGDOM REFERRAL POPULATION. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp 649-650)
- ABSOLUTE NEUTRIPHIL COUNT IS NOT ASSOCIATED WITH THE DEVELOPMENT OF INFECTIONS IN PATIENTS WITH HCV HEPATITIS RECEIVING ANTI VIRAL TREATMENT. HEPATOLOGY, Vol. 52(4) (pp 807A-807A)
- Teaching interests
-
I am engaged in various teaching sessions for undergraduate and postgraduate students and have supervised a number of research placement students, including a CIMA MRes student and visiting clinical fellows.
- Professional activities and memberships
-
I am a Fellow of the Higher Education Academy and a member of the Association of Medical Educators.
- Current projects
-
-
The use of PINP in a primary care setting to monitor osteoporosis (the POSE Study)
This is a project that I lead on and involves the assessment of a bone marker called PINP in a real-life setting in order to check whether patients that are monitored using this marker have better outcomes in terms of bone density, number of fractures and treatment persistence than the patients not monitored. This project is in collaboration with ScHARR and Professor Bo Abrahamsen in Denmark and has received a grant funding by Roche Diagnostics.
-
Osteoclast precursors in patients treated with denosumab
Denosumab is an anti-osteoporotic medication that has proven effective in preventing bone loss and reducing the incidence of fractures. However, on discontinuation of denosumab there is a rebound of bone turnover to 200% of pre-treatment baseline, which is associated with loss of the comparative gains in bone strength, and concerns have arisen amid cases reporting an increase in the incidence of osteoporotic fractures. The aim of this project, is to investigate the effect of denosumab on the osteoclast precursor population in order to elucidate the cellular mechanisms of this phenomenon.
-
Neutrophil migratory function in patients treated with zoledronic acid
Both statins and zoledronic acid target the same metabolic pathway, therefore we suspect the mechanism underlying the reduction in morbidity and mortality in patients with zoledronic acid may be related to an ameliorated function of neutrophils. This is an early stage study, aiming to see what the effect of zoledronic acid is on the migratory function of neutrophils and their ability to engulf and destroy bacteria.
-
Links